anthera pharmaceuticals promotes colin hislop md to chief medical officer nasdaqanth facebook google linkedin twitter email rss jun   previous release  next release pdf add to briefcase file is in briefcase anthera pharmaceuticals promotes colin hislop md to chief medical officer hayward calif june   prnewswire via comtex news network  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing therapeutics to treat serious diseases associated with inflammation and autoimmune disorders today announced colin hislop md has been promoted to the role of chief medical officer of anthera dr hislop replaces james e pennington md who will continue to serve as antheras senior clinical fellow since the early days of anthera colin has done an extraordinary job heading up the advancement of our cardiovascular program and the inlicensing of a6 from amgen we look forward to accelerating our clinical programs under his capable leadership at anthera stated paul f truex president and chief executive officer of anthera pharmaceuticals we greatly appreciate jims hard work mentorship and clinical leadership over the past three years he has been a driving force behind our development strategies and has provided a level of strategic insight that we are fortunate to continue to access in his new role as senior clinical fellow dr hislop has served as antheras senior vice president of cardiovascular products since  prior to joining anthera he was vice president of clinical development for peninsula pharmaceuticals inc where he oversaw three global development programs for peninsulas antiinfective product portfolio including doribaxr doripenem and ceftaroline dr hislop has over  years of drug development expertise in a number of areas including cardiovascular endocrinology allergyasthma and infectious disease while vice president of clinical research at cv therapeutics dr hislop was the development leader for the companys first product ranexar ranolazine and championed the nda efforts for this cardiovascular compound prior to cvt dr hislop spent seven years at proctor and gamble as the worldwide clinical development manager for pgs osteoporosis drug actonelr risedronate sodium he also worked at eli lilly and company in the uk as a medical advisor for the endocrinology group dr hislop has a bsc from university of surrey in medical biochemistry and an md bs from the university of london dr pennington has over  years of experience in the pharmaceutical industry during which he was responsible for  nda and bla approvals in the united states and  product approvals in countries outside the us he joined anthera in  from cotherix inc where he served as executive vice president and chief medical officer of a biopharmaceutical company focused on licensing developing and commercializing therapeutic products for the treatment of cardiovascular diseases previously he was executive vice president medical and scientific affairs and chief medical officer of intermune inc a publiclytraded biopharmaceutical company focused on the development applied research and marketing of lifesaving therapies for pulmonary and hepatic diseases and also served as vice president of biological and biotechnology clinical development of bayer corporation for  years prior to entering the pharmaceutical industry dr pennington also has years of experience in academia at harvard medical school and the university of california san francisco he attended the university of oregon school of medicine to earn his medical degree and is board certified in internal medicine and infectious disease about anthera pharmaceuticals anthera pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation including cardiovascular and autoimmune diseases anthera has one phase  clinical program a and two phase  clinical programs a6 and a a and a inhibit a novel enzyme target known as secretory phospholipase a or spla elevated levels of spla have been implicated in a variety of acute inflammatory conditions including acute coronary syndrome and acute chest syndrome as well as chronic diseases such as stable coronary artery disease or cad antheras phase  product candidate a6 targets elevated levels of blymphocyte stimulator or blys which has been associated with a variety of bcell mediated autoimmune diseases including systemic lupus erythematosus or lupus for more information please visit wwwantheracom safe harbor statement any statements contained in this press release that refer to future events or other nonhistorical matters are forwardlooking statements made pursuant to the safe harbor provisions of the private securities litigation reform act of  these include but are not limited to statements relating to the anticipated initiation of antheras clinical studies anticipated duration and expected results of these studies and the progression of antheras products through future stages of clinical development these forwardlooking statements are based on antheras expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in the companys public filings with the securities and exchange commission including antheras quarterly report on form q for the quarter ended march   anthera disclaims any intent or obligation to update any forwardlooking statements whether because of new information future events or otherwise except as required by applicable law contact juliane snowden of burns mcclellan inc jsnowdenburnsmccom or  source anthera pharmaceuticals inc copyright c  pr newswire all rights reserved colin hislop  anthera pharmaceuticals inc  zoominfocom versartis appoints colin hislop md as chief medical officer nasdaqvsar facebook google linkedin twitter email rss mar  6 previous release  next release pdf add to briefcase file is in briefcase versartis appoints colin hislop md as chief medical officer menlo park calif march  6 globe newswire  versartis inc nasdaqvsar an endocrinefocused biopharmaceutical company that is developing somavaratan vrs7 a novel longacting form of recombinant human growth hormone rhgh for growth hormone deficiency ghd today announced that it has appointed colin hislop md as chief medical officer dr hislop is an experienced drug development clinician with over 7 years of experience in both pharmaceutical and biotechnology companies jay shepard president and chief executive officer said we are very pleased to have colin join the versartis management team he brings unique development leadership and strategic insight to the organization his deep clinical experience throughout the product development process especially in the support of regulatory strategies and initial marketing approvals will make him a valuable addition to our team i look forward to working with colin to further advance our global somavaratan pediatric and adult ghd clinical programs it is a great privilege to be joining versartis at such an exciting time i am exceedingly impressed with the progress that has been made with the companys lead clinical program somavaratan which has the potential to serve a critically important unmet need for patients with ghd i look forward to joining jay and his accomplished leadership team as we work toward bringing somavaratan to market for pediatric and adult ghd patients said colin hislop md dr hislop has broad therapeutic area experience including in endocrine disease he was most recently at anthera pharmaceuticals inc where he was a founding member of the management team and served as the companys chief medical officer before joining anthera dr hislop was vice president clinical development for peninsula pharmaceuticals inc and prior to that vice president clinical development for cv therapeutics inc he began his industry career with eli lilly  company as a medical director for the endocrine portfolio in the uk before moving to procter  gamble co to lead the initial risedronate actonel™ development program dr hislop is a graduate of the middlesex hospital medical school university of london over the course of his career dr hislop has helped secure over  million in private and public equity financing and has supported the inlicensing of compounds for development as well outlicensing and partnership opportunities he has been involved in numerous regulatory interactions for drugs spanning from preind to advisory committee meetings for approval among those drugs with approvals are actoneltm which went on to realize  billion in global sales and ranexatm which was one of the key drivers behind gileads purchase of cv therapeutics for  billion in 9 about versartis inc versartis inc is an endocrinefocused biopharmaceutical company initially developing somavaratan vrs7 a novel longacting form of recombinant human growth hormone in latestage clinical trials for the treatment of growth hormone deficiency ghd in children and adults somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections potentially improving compliance and therefore treatment outcomes versartis clinical trials can be found at wwwversartistrialscom for more information on versartis visit wwwversartiscom cautionary note on forwardlooking statements this press release contains forwardlooking statements for purposes of the safe harbor provisions of the private securities litigation reform act of  forwardlooking statements include statements regarding our intentions or current expectations concerning among other things plans and timing of our clinical trials and the potential for eventual regulatory approval of somavaratan forwardlooking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated we discuss many of these risks in greater detail under the heading risk factors contained in our annual report on form k for the year ended december   which is on file with the securities and exchange commission sec forwardlooking statements are not guarantees of future performance and our actual results may differ materially from the forwardlooking statements contained in this press release any forwardlooking statements that we make in this press release speak only as of the date of this press release we assume no obligation to update our forwardlooking statements after the date of this press release contacts corporate  investors joshua brumm chief financial officer 65 965 irversartiscom corporate communications christine labaree evergreen communications 65 6697 christineevergreencommscom investors nick laudicodavid burke the ruth group 66 56779 nlaudicotheruthgroupcom dburketheruthgroupcom colin hislop  anthera pharmaceuticals inc  zoominfocom   colin hislop  associates  menlo park ca  company information products resources my account talk to a db advisor 7 business directory ca menlo park business services nec business services at noncommercial site colin hislop  associates c colin hislop  associates claim this business  arbor rd menlo park ca 9 get directions 65 7 business info founded  incorporated annual revenue  employee count  industries business services at noncommercial site contacts colin hislop contact business your email address subject message send message company summary colin hislop  associates was founded in  colin hislop  associates specializes in business services at noncommercial site verified status unverified address unverified last verified  phone unverified payment method unverified view full report similar businesses nearby our similar businesses nearby shows similar businesses in their industry and region based on information found in their dun  bradstreet credibility review profile competitive landscape our competitive landscape shows how this business compares to similar businesses in their industry and region based on information found in their dun  bradstreet credibility review profile payments accepted no data hours sunday   monday   tuesday   wednesday   thursday   friday   saturday   c view additional data select from over  networks below to view available data about this business if this data is unavailable or inaccurate and you own or represent this business click here for more information on how you may be able to correct it credibility review google facebookcom yellowbookcom bingcom yellowpagescom merchantcircle tele atlas tomtom twittercom aol mapquest yahoo local applesiri groupon hotfrogcom comcastnet search reachlocal admedia dealsplus shoptopiacom alteryx dogtime media kslcom sirtune americantownscom driverside kudzucom specialsagentcom answerscom egood lawinfocom spotlikescom anywhocom egumball likenesscom spotzot eservicelog mapmyrun technocom apartmentguidecom ezlocalcom eztousecom teleroute aroundmecom metropolistcom therapistscom atlanta newhomes findlawcom time out new york avantar findthebestcom mojopagescom bb yellowpages fivestar software mycitywaycom tripadvisor bckyrdcom giftcardscom mycouponscom beachcaliforniacom golocal7com mymovecom upmesocialcom belo goodinfo newsgazette nokia usdirectorycom carscom nomao centzycom hibu openlistcom chacha search homeplatecom ownlocalcom visikard challamacom homestore patchcom voltari citybot pelopidas vouchd classifiedads hostway placeiq walkscorecom cloudmade hoodoyou planetdiscovercom weddingwirecom powerprofiles where inc contractorscom igolocalcom radiate media wikiocity couponmap indeedcom wimgocom crowdspot innova electronics intellistrand realtorcom datasphere inthemocom replycom yellowbotcom jiwire rocket fuel yellowpagecitycom dmvorg justclicklocalcom dirxion keencom zidstercom photos business credit report receive a onetime comprehensive credit report on this company get full credit report facebook twitter yelp call 7 to speak with a db advisor today customer resources products education center business articles  insights glossary contact us customer support communication preferences search for db duns our company about us company history business credit history careers press releases news success stories hoovers our network partners affiliates blog access to capital entrepreneurial initiative db international supplieredge site links business directory site map pipeda privacy policy website terms of service product license agreement  dun  bradstreet inc 7 all rights reserved versartis appoints colin hislop md as chief medical officer  thestreet action alerts plus access aapjim cramers best stocks for 7charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for 7 commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use 996 thestreet inc all rights reserved djia nasdaq sp 5 market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street versartis appoints colin hislop md as chief medical officer globenewswire mar  6  am edt menlo park calif march  6 globe newswire  versartis inc nasdaqvsar an endocrinefocused biopharmaceutical company that is developing somavaratan vrs7 a novel longacting form of recombinant human growth hormone rhgh for growth hormone deficiency ghd today announced that it has appointed colin hislop md as chief medical officer dr hislop is an experienced drug development clinician with over 7 years of experience in both pharmaceutical and biotechnology companies jay shepard president and chief executive officer said we are very pleased to have colin join the versartis management team he brings unique development leadership and strategic insight to the organization his deep clinical experience throughout the product development process especially in the support of regulatory strategies and initial marketing approvals will make him a valuable addition to our team i look forward to working with colin to further advance our global somavaratan pediatric and adult ghd clinical programs it is a great privilege to be joining versartis at such an exciting time i am exceedingly impressed with the progress that has been made with the companys lead clinical program somavaratan which has the potential to serve a critically important unmet need for patients with ghd i look forward to joining jay and his accomplished leadership team as we work toward bringing somavaratan to market for pediatric and adult ghd patients said colin hislop md dr hislop has broad therapeutic area experience including in endocrine disease he was most recently at anthera pharmaceuticals inc where he was a founding member of the management team and served as the companys chief medical officer before joining anthera dr hislop was vice president clinical development for peninsula pharmaceuticals inc and prior to that vice president clinical development for cv therapeutics inc he began his industry career with eli lilly  company as a medical director for the endocrine portfolio in the uk before moving to procter  gamble co to lead the initial risedronate actonel™ development program dr hislop is a graduate of the middlesex hospital medical school university of london if you liked this article you might like twitter is one of five stocks insiders really love right now insiders at these companies have been scooping up shares in their own organizations lately roberto pedone feb  7  pm est versartis pipeline holds big promise this smallcap biotech name could have further to run bret jensen jan  7  am est versartis pipeline holds big promise this smallcap biotech name could have further to run bret jensen jan  7  am est dont tell anyone insiders are buying these stocks like crazy insiders at infinity pharmaceuticals and ochziff capital management group  among other companies  have been scooping up shares of their own stock lately roberto pedone jan  7  am est trending walmart in focus amid horrific human trafficking incident in texas that causes nine deaths billionaire mark cuban the rise of technology will cause a lot of unemployment trump just resurrected the ugly practice known as civil forfeiture for no reason chipotle is doomed unless it takes this one dramatic measure as snap continues to stumble should it consider selling itself advertising partners 9967 thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers